ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

April 30, 2007 16:17 ET

ALDA Pharmaceuticals Increases Private Placement

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 30, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (the "Company") announces that the private placement disclosed in a new release dated April 4, 2007 of up to 5 million units of the Company (the "Units") at a price of $0.10 per Unit for proceeds to the Company of up to $500,000 is being increased to 8 million Units for proceeds up to $800,000. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of twelve (12) months from the date of the issuance of the purchase warrant and at a price of $0.30 per common share for the subsequent period of twelve (12) months.

As disclosed in a news release dated April 27, 2007, insiders of the Company have completed the sale of 3,205,825 common shares of ALDA at prices ranging from $0.11 to $0.17 per share through the TSX Venture Exchange. The proceeds obtained through the sale of these shares will be used by these insiders to exercise up to 2,775,000 Units of the private placement. Previously, a portion of the proceeds were used to exercise 900,000 share options.

The offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for working capital.

About ALDA Pharmaceuticals Corp.

ALDA's patent-pending T36® therapeutic products contain active ingredients in very low concentrations that act in concert to disrupt the physical structure of all infectious organisms rather than interfering with their metabolic pathways. The competitive advantage is a high degree of effectiveness and safety while preventing microbial resistance, side effects or toxicity. The Company has identified global markets of $10 Billion in its targeted disease areas.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information